LONDON (Reuters) – An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group’s expanding vaccine unit a potential $1 billion boost.
The data suggests the British company’s new shot could be a strong competitor for Merck & Co’s established vaccine Zostavax, which is currently the only product on the market.
BRUSSELS/LONDON (Reuters) – Europe’s top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented.
Thursday’s judgment by the European Court of Justice was made following a case brought in Britain by U.S. company International Stem Cell Corporation over whether it could patent processes covering the use of human egg cells.
LONDON (Reuters) – British scientists have developed a new use for 3D printing, putting it to work to create personalized replica models of cancerous parts of the body to allow doctors to target tumors more precisely.
The initiative is the latest example of medicine harnessing the rapidly emerging technology, which has already been used to manufacture some medical implants.